首页> 外文期刊>European surgical research >Outcomes of Pure Laparoscopic versus Open Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients: A Case-Control Study with Propensity Score Matching
【24h】

Outcomes of Pure Laparoscopic versus Open Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients: A Case-Control Study with Propensity Score Matching

机译:腹腔镜与开放式肝切除术对肝硬化患者肝癌的结果:倾向评分匹配的病例对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Purpose: Laparoscopic hepatic resection (LH) for hepatocellular carcinoma (HCC) has gradually gained ground as a safe and minimally invasive treatment, although LH for cirrhotic patients remains challenging. Methods: Between January 2007 and August 2014, 28 and 57 patients with histologically proven cirrhosis (histological activity index, fibrosis score 4) underwent pure LH and open hepatic resection (OH; less than segmentectomy), respectively, for peripheral HCC <= 5 cm. To correct the difference in clinicopathological factors, including difficulty scores, between the two groups, propensity score matching was used at a 1: 1 ratio, which resulted in a comparison of 20 patients per group. We compared the short-and long-term outcomes of LH and OH to investigate the efficacy of LH. Results: Clinicopathological variables, including difficulty scores, were well balanced between the two groups. The incidence of complications and mean intraoperative blood loss were lower in the LH group than the OH group (0 vs. 45% and 180 vs. 440 ml, p = 0.001 and 0.04, respectively). The 3-year disease-free survival rate was 42% in the LH group and 30% in the OH group (p = 0.533), whereas the 5-year overall survival rates were 46 and 60%, respectively (p = 0.606). Conclusions: LH is a safe and effective treatment option for cirrhotic patients with HCC in terms of intraoperative blood loss and morbidity. (C) 2015 S. Karger AG, Basel
机译:背景/目的:尽管对于肝硬化患者来说,腹腔镜肝切除术(LH)仍是一项安全且微创的治疗方法,但它已逐渐成为一种安全且微创的治疗方法。方法:在2007年1月至2014年8月之间,分别对28例和57例经组织学证实为肝硬化(组织活性指数,纤维化评分为4)的患者进行了纯LH和开放性肝切除术(OH;小于节段切除术),其周围HCC <= 5 cm 。为了纠正两组之间临床病理因素(包括难度评分)的差异,倾向评分匹配以1:1的比例使用,每组对20名患者进行了比较。我们比较了LH和OH的短期和长期结果,以研究LH的疗效。结果:两组的临床病理变量,包括难度评分,均取得了很好的平衡。 LH组的并发症发生率和术中平均失血量比OH组低(0 vs. 45%和180 vs. 440 ml,p = 0.001和0.04)。 LH组的3年无病生存率分别为OH组的42%和OH组的30%(p = 0.533),而5年总生存率分别为46%和60%(p = 0.606)。结论:就术中失血和发病率而言,LH是治疗肝硬化肝癌的安全有效的选择。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号